Insider Buying: PureTech Health (LON:PRTC) Insider Buys £939.44 in Stock

PureTech Health plc (LON:PRTC) insider John LaMattina purchased 93,944 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was acquired at an average price of GBX 1 per share, for a total transaction of £939.44.

John LaMattina also recently made the following trade(s):

• On Wednesday, July 8th, John LaMattina acquired 50,000 shares of PureTech Health stock. The stock was purchased at an average cost of GBX 119 per share, with a total value of £59,500.

PureTech Health Price Performance

PRTC stock traded down GBX 0.48 during trading on Friday, hitting GBX 119.12. The company had a trading volume of 512,639 shares, compared to its average volume of 1,072,302. PureTech Health plc has a fifty-two week low of GBX 104.71 and a fifty-two week high of GBX 146.40. The business has a 50 day moving average of GBX 127.71 and a 200 day moving average of GBX 126.71. The firm has a market capitalization of £289.96 million, a price-to-earnings ratio of -2.59 and a beta of 0.79. The company has a current ratio of 6.59, a quick ratio of 2.51 and a debt-to-equity ratio of 6.33.

Analyst Ratings Changes

Separately, Peel Hunt reaffirmed a “buy” rating and issued a GBX 508 target price on shares of PureTech Health in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of GBX 508.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.